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native. Only direct medical costs were considered. Costs and outcomes were dis-
counted at 5% yearly. The outcomes considered were life years (LY) and quality
adjusted life years (QALY). RESULTS: The incremental cost-effectiveness analysis
demonstrated that AA is the most economically attractive medication. When the
incremental cost-effectiveness ratio (ICER) for LY and QALY gained was evaluated,
AA was dominant with regards to C, being more effective (LY: 1.3559 vs 1.2895;
QALY: 0.7977 vs 0.7329) with lower costs (R$79,974 vs R$90,025).CONCLUSIONS:AA
is the best therapeutic option, with the best cost-effectiveness ratio, versus C for
the treatment of patients diagnosed with advanced mCRPC under Brazilian private
perspective.
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OBJECTIVES: To identify the cost effectiveness ratio of Vemurafenib in the treat-
ment of patients of the public health care institutions in Mexico, with BRAF positive
mutation (BRFAF ) metastatic or advanced melanoma, compared with dacarba-
zina and temozolomide. METHODS: A Markov model was developed with monthly
cycles, with 4 health states: clinical benefit, stable disease, disease progression and
death, considering the adverse events as transitory stages, during a 5 year time
horizon. A cost effectiveness analysis was developed, where the transition proba-
bilities between the different health’s states considered, are the basis to estimate
how many life years (LY) the patients will achieve with the different treatment
alternatives. The costing method used in this study is the direct medical costs,
expressed in US dollars. RESULTS: In the pharmacoeconomic analysis, Vemu-
rafenib was the most effective treatment producing a mean of 2.15 LY per patient
during the 5 year time horizon, 1.17 additional LY to those produced by dacarbazine
(.98 LY) or temozolomide (0.98 LY). This shows that Vemurafenib is the most effec-
tive alternative for this patient due the effectiveness is 2.2 times higher compared
to dacarbazine and temozolomide. CONCLUSIONS: Given the current worldwide
discussion regarding the cost-effectiveness (CE) of orphan drugs, is considered
necessary to evaluate these drugs under a different criteria that those used for
drugs that are not orphans. So patients, who have rare and deadly diseases, can
have the opportunity to live longer and better.
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OBJECTIVES: To perform a cost-effectiveness analysis based on markers of re-
sponse/resistance including biological therapies available in Spain for metastasic
colorectal cancer (mCRC). METHODS: Incremental cost-effectiveness ratio (ICER)
per life-year gained (LYG) and progression-free year gained were calculated based
on predictive markers for mCRC. Efficacy data include randomized trials (RT) that
guided on-label uses of bevacizumab and cetuximab. Control arms from these
trials were used as reference scenario. Markers of clinical benefit (biological &
radiological) were included. Toxicity as predictor of efficacy was excluded for any
therapy. Prices for drugs in Spain were assumed to represent the best-value for
each drug including all possibilities to reduce pharmacy costs. For 1st line, median
duration of therapy reported by RT was used to calculate the final budget. 70kg and
1.7 m were used as reference for patients dose calculations. If accessible, HR for PFS
and OS were used instead of medians. RESULTS: K-Ras status and early response
measured by computed tomography at 8 weeks were used as predictors of resis-
tance and increased efficacy for cetuximab-based combinations. We have not iden-
tified any predictor marker for other drugs from RT. In this regard,
FOLFIRIcetuximab combination obtained an ICER below the widely-proposed
Spanish threshold of 30,000 € per LYG if patients harbored wild type (wt) K-Ras
tumors and evidenced an objective response at 8 weeks. Other ICERs for different
schedules were too distant from this limit. Multivariate analysis confirmed the
robustness of results. CONCLUSIONS: First-line FOLFIRIcetuximab therapy for wt
K-Ras patients that get an objective response measured by CT at 8 weeks is the only
cost- effective therapy option for mCRC below usual health economics thresholds
for Spain. Our results are critical to design cost-effectiveness based clinical guide-
lines for mCRC that will contribute to financial sustainability of public health sys-
tem in Spain.
PCN89
COST EFFECTIVENESS OF TREATMENT WITH NEW 6-MONTH LEUPRORELIN
ACETATE FORMULATION IN PATIENTS WITH ADVANCED PROSTATE CANCER
Tundia NL1, Fuldeore M2, Gruca D3, Hass S2, Bacher P2, Bodhani A2
1University of Cincinnati, Cincinnati, OH, USA, 2Abbott Laboratories, Abbott Park, IL, USA,
3Abbott Laboratories, Ludwigshafen, Germany
OBJECTIVES: To conduct a cost effectiveness analysis (CEA) comparing 3.75 mg
1-month (1M), 11.25 mg 3-month (3M) and 30 mg 6-month (6M) leuprorelin acetate
formulations (LAF) in patients with advanced prostate cancer (APC) in Switzerland.
METHODS: A CEA was performed from the payer perspective using a decision-tree
model. Total treatment costs per patient per year and cost-effectiveness ratios
(CER) were calculated. Clinical efficacy and safety data (serum testosterone
50ng/dl and adverse drug reactions /ADRs/) for LAF were obtained from random-
ized trials. Direct medical costs (drug, physician consultation and drug adminis-
tration, and ADRs), reported as 2011 in Swiss Francs (CHF), were obtained from a
Swiss health care database (Tarmed) and doctor interviews. We assumed a patient
would visit the physician’s office a minimum of 12, 4 and 2 times/year when treated
with 1M, 3M and 6M LAF, respectively. The modeled annual costs were extrapo-
lated to the median survival time (3.1 years) of a patient with APC. One and two-
way sensitivity analysis was conducted to check robustness of the model.
RESULTS: In Switzerland, the annual cost associated with 6M LAF (CHF 3,320) was
lower than that associated with 3M (CHF 4,411) and 1M (CHF 5,672) LAF. The lifetime
costs of treatment with 1M, 3M and 6M LAF were CHF 16,349, CHF 12,715 and CHF
9,664, respectively (Discount rate3%). Annual cost savings associated with the 6M
formulation were 41% and 24% over the 1M and 3M formulations, respectively. 1M
and 3M LAF were dominated with higher overall costs and lower effectiveness
compared to the 6M formulation (CERCHF 5,154/effectiveness). Sensitivity anal-
ysis confirmed the robustness of the results. CONCLUSIONS: Results suggest 6M
LAF as a cost-effective strategy for treating patients with APC. Dosing frequency,
reduction of possible local side reactions and number of outpatient visits could be
potential factors in optimizing drug-related treatment costs for APC.
PCN90
COST EFFECTIVENESS ANALYSIS OF BENDAMUSTINE AS FIRST LINE
TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE NETHERLANDS
Vandekerckhove S1, Holtzer-Goor K2, Van Den Steen D1, van Megen Y3, Huijgens P4,
Lamotte M1, Uyl- de Groot C5
1IMS Health, Vilvoorde, Belgium, 2iMTA, Rotterdam, Zuid Holland, The Netherlands,
3Mundipharma Pharmaceuticals, HOEVELAKEN, The Netherlands, 4VU University Medical
Center, Amsterdam, The Netherlands, 5Erasmus University, Rotterdam, The Netherlands
OBJECTIVES: To compare, from a Dutch health care payer perspective, bendamus-
tine against chlorambucil. The latter is the current first line treatment for CLL
patients with Binet stage B or C for whom fludarabine combination therapy is not
appropriate. METHODS: A Markov model to reflect the treatment sequence of pa-
tients with CLL in the Netherlands was developed in Treeage pro suite 2009 linked
to Excel 2007. Three treatment lines were modelled before patients reached best
supportive care. This treatment path was supported by a Dutch CLL expert panel.
Transition probabilities were derived from clinical trials, the expert panel and
Dutch mortality statistics. Health care resource utilisation was estimated for each
health state using clinical guidelines and the expert panel. Model outcomes were
life years (LY), quality-adjusted life years (QALYs), progression free life years (PFLY),
and total CLL related health care costs (2011 values). The model time horizon was
10 years and monthly cycles were used. Annual discounting of 4%/1,5% was applied
on costs and effects, respectively. RESULTS: The analysis showed that patients
with bendamustine and chlorambucil as first line treatment generated 3.77 and
2.21 QALYs, respectively. The total average costs amounted to €79,328 for benda-
mustine, and €67,172 for chlorambucil. The incremental cost effectiveness ratio
(ICER) of bendamustine compared to chlorambucil was €7,809 per QALY gained.
The incremental cost per LY and PFLY gained were €7,374 and €6,908. The cost-
effectiveness acceptability curve indicated that the probability that bendamustine
was cost-effective approximated 95% at a threshold of €20,000 per QALY.
CONCLUSIONS: Bendamustine compared to chlorambucil, in previously untreated
Binet B or C CLL patients for whom fludarabine combination therapy is not appro-
priate, generated an ICER of €7,809 per QALY gained. This indicated that benda-
mustine is cost-effective as first line treatment for CLL in the Netherlands.
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OBJECTIVES: Previous analyses have projected the health and economic impact of
Herceptin® (trastuzumab) in HER2-positive (HER2) breast cancer over the product
life cycle in the US and major EU markets from a payer perspective. The objective of
this analysis is to project the overall product life cycle cost-effectiveness of trastu-
zumab in HER2 breast cancer treatment in Portugal, a relatively small (10.6 mil-
lion inhabitants), lower income EU country, considering the societal perspective.
METHODS: Using a product life cycle modeling approach, the projected life cycle
(“dynamic”) incremental cost-utility ratio (ICUR) was estimated for the period 2000
to 2020. The model combines projected “static” ICURs for trastuzumab in early
(eBC) and metastatic (mBC) HER2 BC based on the literature with epidemiological
projections of annual HER2 BC disease incidence and the utilization of trastu-
zumab in Portugal over this 21-year period. The major societal saving is reduced
work loss for women with eBC who receive trastuzumab. The dynamic model
considers both a payer and societal perspective over a lifetime horizon. All costs (in
2012 Euros) and outcomes are discounted at 3.0% to the year 2000. RESULTS: The
model projects that over the 21-year period, 10,900 women would receive trastu-
zumab treatment for eBC, and 5,200 women for mBC. Given the respective ICURs
from a payer perspective for eBC (11,000€ per quality adjusted life year (QALY)) and
for mBC (43,000€ per QALY), the overall dynamic ICUR is approximately 15,000€ per
QALY from payer perspective. Taking a societal perspective, this is projected to be
reduced by at least 15%. CONCLUSIONS: Taking a dynamic—and societal—life cy-
cle perspective, in the case of Portugal, over 16,000 QALYs are projected to be
gained through the year 2020 at a very favorable ICUR of less than 13,000€per QALY.
Viewed over the product life cycle, trastuzumab for breast cancer would be consid-
ered cost-effective in Portugal.
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